The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Systematic review: adherence issues in the treatment of ulcerative colitis
Open accessAbstract
Summary: Ulcerative colitis is a chronic inflammatory and debilitating disease requiring lifelong treatment. First‐line therapy for ulcerative colitis is 5‐aminosalicylic acid, which suffers from poor patient adherence outside the clinical trial setting. Formulations to deliver 5‐aminosalicylic acid to the disease activity site, both orally and topically, are often inconvenient and require multiple daily dosing. Such regimens can interfere with normal life and reduce the overall quality of life, negatively impacting on treatment adherence and leading to poorer long‐term outcomes. These include increased morbidity with an elevated risk of symptomatic relapse, possible greater risk of colorectal cancer and higher overall costs of care. Ulcerative colitis patients cite treatment regimen complexity, tablet quantity and dose frequency as key negative influencers of adherence. Solutions to these issues include addressing patient concerns, simplifying daily regimens and utilizing new formulations such as micropellet and multimatrix oral formulations, rectal gel and once‐daily suppository formulations. This review examines the prevalence and impact of non‐adherence to 5‐aminosalicylic acid therapy among patients with ulcerative colitis, as well as drug delivery strategies that may enhance dosing regimens to improve patient acceptability, adherence and long‐term clinical outcomes. It is a combination of understanding patient behaviour, recognizing signs of non‐adherent behaviour and utilizing management strategies to change behaviour that will improve patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adherence to Long‐Term Therapies: Evidence for Action
Burkhart, P. V., & Sabaté, E. (2003) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2003.tb00001.x · Cited by 2,526
Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis
Robin DiMatteo, M., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002) · Medical Care · doi:10.1097/00005650-200209000-00009 · Cited by 1,490
A systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203
Brian Haynes, R., Ann McKibbon, K., & Kanani, R. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01073-2 · Cited by 645
Colorectal cancer prevention in ulcerative colitis: a case‐control study
Eaden, Abrams, Ekbom, Jackson, & Mayberry (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00698.x · Cited by 577
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis
Kane, S., Huo, D., Aikens, J., & Hanauer, S. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01383-9 · Cited by 569
Self-citationVelayos, F. S., Terdiman, J. P., & Walsh, J. M. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41442.x · Cited by 548
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Wang, Y., Parker, C. E., Bhanji, T., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub4 · Cited by 494
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Wang, Y., Parker, C. E., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub4 · Cited by 483
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
Kane, S. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)03245-2 · Cited by 429
Self-citation
Cited by
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60150-0 · Cited by 2,078
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
The impact of medication regimen factors on adherence to chronic treatment: a review of literature
Ingersoll, K. S., & Cohen, J. (2008) · Journal of Behavioral Medicine · doi:10.1007/s10865-007-9147-y · Cited by 583
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Wang, Y., Parker, C. E., Bhanji, T., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub4 · Cited by 494
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Wang, Y., Parker, C. E., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub4 · Cited by 483
AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis
Ko, C. W., Singh, S., Feuerstein, J. D., Falck-Ytter, C., Falck-Ytter, Y., Cross, R. K., Crockett, S., Falck-Ytter, Y., Feuerstein, J., Flamm, S., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.009 · Cited by 334
Foundations of gastrointestinal-based drug delivery and future developments
Chu, J. N., & Traverso, G. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00539-w · Cited by 289
Jackson, C. A., Clatworthy, J., Robinson, A., & Horne, R. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.685 · Cited by 286
Horne, R., Parham, R., Driscoll, R., & Robinson, A. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20846 · Cited by 267
Nahon, S., Lahmek, P., Saas, C., Durance, C., Olympie, A., Lesgourgues, B., & Gendre, J.-P. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21482 · Cited by 102
Metadata
- Authors
- KANE, S. V.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-02-14
- Volume
- 23
- Issue
- 5
- Pages
- 577-585
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2059964008
- Cited by
- 294
- References
- 45
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.